dc.contributor | Mena-Enriquez, M., Instituto de Biología Molecular en Medicina Y Terapia Génica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada, Núm. 950 Col. Independencia, 44340, Guadalajara, Jal., Mexico; Flores-Contreras, L., Instituto de Biología Molecular en Medicina Y Terapia Génica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada, Núm. 950 Col. Independencia, 44340, Guadalajara, Jal., Mexico; Armendáriz-Borunda, J., Instituto de Biología Molecular en Medicina Y Terapia Génica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada, Núm. 950 Col. Independencia, 44340, Guadalajara, Jal., Mexico | |
dc.description.abstract | Viral vectors based on adeno-associated virus (AAV) are widely used in gene therapy protocols, because they have characteristics that make them valuable for the treatment of genetic and chronic degenerative diseases. AAV2 serotype had been the best characterized to date. However, the AAV vectors developed from other serotypes is of special interest, since they have organ-specific tropism which increases their potential for transgene delivery to target cells for performing their therapeutic effects. This article summarizes AAV generalities, methods for their production and purification. It also discusses the use of these vectors in vitro, in vivo and their application in gene therapy clinical trials. | |